Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 59%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Natera is a promising company with a strong product portfolio, highlighted by the success of its MRD test, Signatera, in predicting survival and potential for expansion. Its strong financial performance and expected revenue growth, along with upcoming catalysts, make it an attractive investment opportunity. However, Natera will need to navigate competition and maintain investor interest in order to continue its success.

Bears say

Natera is a company with a promising portfolio of advanced personalized diagnostic offerings in the areas of oncology, organ health, and women's health. However, its overreliance on Signatera, and the potential for penetration of MRD testing to stall, make it a risky investment. Additionally, the company's inconsistent track record of catalyst realization and the potential for ASP expansion to stall could hinder future growth, and its current valuation is already at a premium to its peers.

Natera (NTRA) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 59% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 17 analysts, Natera (NTRA) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $273.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $273.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.